Fosamax Safety Signals & FDA Actions: What Clinicians and Patients Need to Know

How Alendronate Works: Mechanism at the Molecular Level

Alendronate belongs to the nitrogen-containing bisphosphonate class. Its antiresorptive effect comes from a precise intracellular target inside the osteoclast, not from a systemic hormone or receptor agonism. Understanding this mechanism is the foundation for understanding every downstream safety signal.

Farnesyl Pyrophosphate Synthase Inhibition

After oral ingestion, alendronate is absorbed (approximately 0.7% bioavailability under fasting conditions), deposited at sites of active bone remodeling, and internalized by osteoclasts during resorption [1]. Inside the osteoclast, it inhibits farnesyl pyrophosphate synthase (FPPS), an enzyme in the mevalonate pathway [2]. FPPS inhibition blocks the prenylation of small GTPase signaling proteins, including Ras, Rho, and Rac. Without functional prenylated GTPases, the osteoclast cytoskeleton disassembles, the ruffled border collapses, and the cell undergoes apoptosis within hours [2].

Why Suppression Persists After Stopping

Bisphosphonates bind hydroxyapatite with very high affinity. Alendronate's skeletal half-life exceeds 10 years [3]. This prolonged retention explains both the drug's durable antifracture effect after discontinuation and the persistence of adverse effects (particularly atypical fracture risk and osteonecrosis of the jaw) long after a patient stops therapy.

Downstream Effect on Bone Turnover Markers

Serum C-terminal telopeptide (CTX) and urine N-telopeptide (NTX) fall by 50 to 70% within 3 to 6 months of starting 70 mg weekly dosing [4]. The FIT trial (N=2,027) showed that this suppression of resorption markers correlated with a 47% reduction in morphometric vertebral fractures over 3 years (RR 0.53, 95% CI 0.41 to 0.68) and a 51% reduction in clinical vertebral fractures (P<0.001) [5].

The FDA's Regulatory Timeline for Alendronate

The FDA's actions on alendronate span more than two decades and mirror the post-marketing evolution of every major drug class: early approval based on fracture endpoints, followed by accumulating pharmacovigilance data triggering label revisions, safety communications, and formal review cycles.

Original Approval and Early Label

The FDA approved alendronate (Fosamax, Merck) in September 1995 for prevention and treatment of postmenopausal osteoporosis [6]. The original label carried warnings for upper gastrointestinal (GI) adverse events based on pre-approval clinical data showing esophageal ulceration in patients who did not follow upright-posture instructions. The requirement to take alendronate with 6 to 8 oz of plain water and remain upright for at least 30 minutes was embedded in the original prescribing information.

2008 to 2009: Esophageal Cancer Signal

In October 2008, the FDA issued a safety update after reviewing 23 foreign (primarily European) spontaneous reports of esophageal cancer in patients taking oral bisphosphonates, including alendronate [7]. The agency added strengthened language to the Warnings and Precautions section. A 2010 observational analysis published in BMJ (N=approximately 41,000 bisphosphonate users) reported an adjusted hazard ratio of 1.30 (95% CI 1.02 to 1.66) for esophageal cancer in users vs. Nonusers [8]. However, a separate nested case-control study in the same journal found no statistically significant association (OR 0.97, 95% CI 0.57 to 1.65) [9]. The FDA concluded the data were "inconsistent" and did not support a definitive causal relationship, but retained the strengthened esophageal warning in labeling [7]. Patients with Barrett's esophagus or active esophageal disease remain contraindicated per current labeling [6].

2010: Atypical Femur Fracture Safety Communication

The FDA issued a Drug Safety Communication in October 2010 requiring new label language about atypical subtrochanteric and diaphyseal femur fractures [10]. These fractures occur at the lateral cortex with minimal or no trauma, often preceded by prodromal thigh pain for weeks to months. The FDA's action followed a task force report from the American Society for Bone and Mineral Research (ASBMR), which reviewed 310 cases and defined diagnostic criteria [11].

The 2011 ASBMR task force report estimated the population-attributable risk: among patients taking bisphosphonates for more than 5 years, the absolute risk of atypical femur fracture was approximately 100 per 100,000 person-years, compared with 2 per 100,000 person-years in non-users [11]. A Swedish population study (N=12,777 atypical fracture cases) calculated a rate ratio of 47.3 (95% CI 25.6 to 87.3) for bisphosphonate use, but the absolute excess risk was still only 5 additional fractures per 10,000 patients per year [12].

2011: Osteonecrosis of the Jaw Label Update

The FDA required updated ONJ language in bisphosphonate labeling in 2011 [6]. ONJ had been described in oncology patients receiving high-dose intravenous bisphosphonates since 2003, but post-marketing reports extended the signal to patients taking oral agents for osteoporosis [13]. The absolute risk for oral bisphosphonate users is substantially lower than for IV bisphosphonate users in oncology: estimated at 1 in 10,000 to 1 in 100,000 patient-years vs. 1 in 100 in the oncology IV setting [13].

2012: FDA Review of Long-Term Use Safety

In September 2011, the FDA convened an advisory committee to examine whether there was a defined safe duration of bisphosphonate therapy [14]. The committee reviewed data from the FLEX trial and HORIZON Key Fracture Trial extension. The FDA did not mandate a specific duration limit but updated labeling to state that the optimal duration had not been established and that re-evaluation of the need for continued therapy should occur periodically [6].

Esophageal Reactions: The Black-Box Warning in Detail

Alendronate's black-box warning addresses esophageal adverse reactions. Severe cases, including esophagitis, esophageal ulcers, and esophageal erosions, have been reported in patients who violated the dosing instructions, had pre-existing esophageal motility disorders, or failed to remain upright post-dose [6].

Mechanism of Esophageal Injury

Alendronate tablets that remain in contact with the esophageal mucosa cause direct caustic injury. The drug's pH in solution is acidic, and prolonged contact disrupts the mucosal barrier. Post-marketing case reports submitted to the FDA MedWatch system identified esophageal stricture requiring dilation in a subset of patients [7].

Practical Prescribing Points

The instructions are specific and non-negotiable for safe use. Patients must swallow the tablet with at least 180 mL of plain water (no juice, coffee, or mineral water), take it on an empty stomach at least 30 minutes before any food or other medication, and remain fully upright (sitting or standing) for at least 30 minutes afterward [6]. Patients who cannot comply with these instructions (bedbound patients, severe GERD, known esophageal stricture) should not receive oral alendronate.

Atypical Femur Fractures: Risk Stratification and Clinical Management

The atypical femur fracture signal is the most discussed safety concern for long-term alendronate use, and it illustrates the tension between antifracture benefit and an uncommon but serious adverse event.

Diagnostic Criteria

The ASBMR 2013 revised task force criteria define an atypical femur fracture as a fracture located between the lesser trochanter and the supracondylar flare, associated with minimal or no trauma, with a transverse or short oblique orientation, non-comminuted, and associated with a periosteal or endosteal stress reaction at the lateral cortex [11]. Bilateral involvement occurs in up to 28% of cases; contralateral X-ray or MRI is warranted in any confirmed case [11].

Duration-Dependent Risk

Risk rises sharply with duration of use. A large Kaiser Permanente cohort study (N=196,129 bisphosphonate users) found that atypical femur fracture incidence was 1.78 per 100,000 person-years for use under 2 years, rising to 113.1 per 100,000 person-years after 8 or more years of continuous use [15]. This duration-dependent pattern is the primary rationale for the drug holiday strategy.

Prodromal Symptoms and Imaging

Up to 70% of patients who develop atypical femur fractures report antecedent thigh or groin pain [11]. When a patient on long-term alendronate (over 5 years) reports new thigh pain, plain radiographs should be obtained. A "beaking" or cortical thickening on the lateral femoral cortex is the classic early radiographic sign. MRI or bone scan is more sensitive for early stress reactions before frank fracture lines appear [16].

The HealthRX clinical framework for managing a patient with prodromal thigh pain on long-term bisphosphonate therapy: (1) obtain bilateral plain femur X-rays; (2) if inconclusive, proceed to MRI of both femurs; (3) discontinue bisphosphonate immediately; (4) refer to orthopedics for prophylactic nailing consideration if a stress fracture is confirmed; (5) consider teriparatide (20 mcg/day SC) as bridging anabolic therapy to accelerate cortical healing, based on case series data [16].

Osteonecrosis of the Jaw: Absolute Risk in Context

ONJ is defined as exposed or necrotic bone in the maxillofacial region persisting for more than 8 weeks in a patient taking an antiresorptive agent, without a history of head and neck radiation or metastatic jaw disease [13].

Risk Factors

The major modifiable risk factor is invasive dental procedures, particularly tooth extractions and dental implant placement. A meta-analysis of 27 studies (N=2,408 ONJ cases) found that tooth extraction was the most common precipitating event in 52% of oral bisphosphonate-related ONJ cases [13]. Other risk factors include glucocorticoid use, diabetes, smoking, and poor oral hygiene.

Absolute Risk Numbers for Patient Counseling

For patients taking oral bisphosphonates for osteoporosis, the estimated ONJ risk is 0.001% to 0.01% per year [13]. This compares favorably with the fracture risk being prevented. A patient with a T-score of minus 2.5 and a prior vertebral fracture has approximately a 20% chance of another vertebral fracture over 5 years without treatment [5]; ONJ risk over the same 5-year period on oral alendronate would be 0.005% to 0.05%.

Pre-Dental-Procedure Management

The American Dental Association and the American Association of Oral and Maxillofacial Surgeons recommend completing any needed invasive dental work before starting bisphosphonate therapy when possible [13]. For patients already on therapy, the decision to pause bisphosphonate before elective extraction is controversial. Given the drug's skeletal half-life exceeding 10 years, a 2-month drug pause does not meaningfully lower bone CTX in most patients and has no proven ONJ prevention benefit [13]. The FDA label does not mandate a pre-procedure drug holiday for ONJ prevention.

The Drug Holiday: FLEX Trial Evidence and Current Guidance

The drug holiday concept acknowledges that alendronate's skeletal retention allows continued antifracture protection even after discontinuation, while persistent use extends the duration of cortical oversuppression that may contribute to atypical fractures.

FLEX Trial Design and Findings

The FLEX trial (Fracture Intervention Trial Long-Term Extension, N=1,099) randomized women who had completed 5 years of alendronate to continue for an additional 5 years or switch to placebo [17]. After 10 total years, continuation vs. Discontinuation did not differ significantly in hip fracture risk (2.9% vs. 3.8%, P<0.001 threshold not met) or morphometric vertebral fracture risk in the overall population. Patients who were at highest baseline fracture risk (T-score below minus 3.5 at the femoral neck or a prior clinical vertebral fracture) showed a trend toward benefit from continuation [17]. The FLEX authors concluded that a drug holiday after 5 years is appropriate for patients who do not have a femoral neck T-score below minus 3.5 or a recent fracture [17].

Current Guideline Recommendations

The 2022 American College of Physicians (ACP) clinical guideline recommends pharmacologic treatment for 5 years in women with osteoporosis and then reassessment [18]. The Endocrine Society's 2019 osteoporosis guideline states: "For patients treated with bisphosphonates for 5 years who are at low risk of fracture (no prior hip or vertebral fracture, femoral neck T-score above minus 2.5), a drug holiday of 2 to 3 years is reasonable" [19]. Bone turnover markers or DXA should guide the decision to restart; a rise in CTX above the premenopausal reference range or bone density loss exceeding the least significant change (typically 3 to 5% at the lumbar spine) are reasonable restart triggers [19].

What Happens to Bone Density During a Holiday

In FLEX, lumbar spine BMD declined by 2.4% during the 5-year off period vs. Continued alendronate, but remained above pre-treatment baseline [17]. Total hip BMD declined by 3.7% during the holiday. These are clinically acceptable losses in lower-risk patients, given the drug's persistent antifracture activity mediated by retained skeletal alendronate.

Renal Safety and Contraindications

Alendronate is contraindicated in patients with creatinine clearance (CrCl) below 35 mL/min [6]. In patients with CrCl above 35 mL/min, no dose adjustment is required. The FDA label does not set an upper age limit for use, though clinical judgment about fall risk, life expectancy, and comorbidities is appropriate.

Hypocalcemia must be corrected before initiating alendronate. The drug lowers serum calcium transiently by reducing bone resorption; in a patient already hypocalcemic, this can precipitate symptomatic hypocalcemia or secondary hyperparathyroidism [6]. Vitamin D deficiency (25-OH vitamin D below 20 ng/mL) should also be corrected first, since an adequate vitamin D level is required for the calcium homeostasis that alendronate disrupts [4].

Musculoskeletal Pain: An Underrecognized Signal

In January 2008, the FDA issued a safety alert about severe and sometimes incapacitating bone, joint, and muscle pain in patients taking bisphosphonates [20]. The pain can begin days to months after initiating therapy. It differs from the transient acute-phase reaction (flu-like symptoms, fever) seen in 10 to 27% of patients starting IV bisphosphonates, which resolves within 72 hours [20].

The FDA MedWatch database contained reports of patients who had been disabled for months with musculoskeletal pain that resolved only after stopping the bisphosphonate. The agency required label changes across the class in 2008 [20]. Clinicians should ask about new-onset severe musculoskeletal pain at every follow-up visit for patients on alendronate and consider a trial off the drug if no other explanation is found.

Pregnancy, Lactation, and Special Populations

Alendronate is FDA Pregnancy Category D (old classification) / mapped to "use contraindicated" under the 2015 Pregnancy and Lactation Labeling Rule [6]. Animal studies show fetal skeletal abnormalities at doses above the human equivalent. Bisphosphonates cross the placenta and may deposit in fetal bone; case reports describe neonatal hypocalcemia in infants of mothers who received IV bisphosphonates [21].

Premenopausal use requires careful counseling. In premenopausal women with glucocorticoid-induced osteoporosis or secondary osteoporosis, alendronate may be used but only with confirmed effective contraception [6]. The skeletal retention means that even a drug holiday of 6 to 12 months before a planned pregnancy does not eliminate fetal exposure risk [21].

Benefit-Risk at the Population Level

Absolute risk reduction numbers anchor the benefit-risk conversation. In the FIT trial (N=2,027 women with low bone density), alendronate reduced clinical vertebral fracture over 3 years by 3.8 percentage points absolute (5.0% placebo vs. 1.2% alendronate) [5]. Hip fracture was reduced by 1.1 percentage points (2.2% vs. 1.1%) [5]. Weighed against an ONJ risk of roughly 0.005% to 0.05% over 5 years and an atypical femur fracture risk of roughly 0.05% to 0.1% over 5 years, the benefit-risk ratio strongly favors treatment in patients with established osteoporosis or prior fragility fracture.

The calculus shifts in patients with osteopenia, no prior fracture, a low FRAX score, and planned use beyond 10 years. In that subgroup, the fracture risk being prevented may approach the atypical fracture risk being incurred. This is precisely the population for whom the drug holiday concept is most relevant.

Patients deserve specific numbers, not reassurances. Telling a patient "the risk of atypical fracture is very low" is less useful than stating: among 10,000 patients taking alendronate for 5 years, approximately 5 to 10 will develop an atypical femur fracture while approximately 190 will avoid a clinical vertebral fracture they would otherwise have sustained.